Yeztugo, a twice-yearly shot, could be the catalyst for stopping a recent spike in new HIV diagnoses. It's now available in ...

Milestone Pharmaceuticals Inc. is a strong buy after a 37% drop post-Cardamyst FDA approval. Click for this updated look at ...

Mark Cuban’s healthcare strategy targets high drug costs, insurance complexity and transparency, offering a simpler model ...

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access. But having a product ...

The recent federal reforms to pharmacy benefit managers are a meaningful step in the right direction, but the work is not ...

Coverage of Lilly’s obesity medications is expanding in the near future. Here’s why that matters.

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and ...

“The Seventh Amendment entitles litigants to a jury trial unless the claim would have been heard, and the remedy awarded, by courts of equity at the Founding," Judge Julius Richardson wrote for the ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

When 22-year-old Cole Schmidtknecht walked up to the pharmacy counter, he learned his Advair Diskus inhaler had jumped from under $70 to over $500. He walked away without the medicine. Within a week, ...

While PBM reforms that passed earlier this year will spur further changes in the way business is conducted, it’s anti-trust ...

Milestone Pharma (MIST) stays a Hold after Q1 misses and a tough CARDAMYST launch; PSVT pricing, uptake, and payer risk loom.